BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34930165)

  • 1. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
    BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of
    Gupta S; Rajappa S; Advani S; Agarwal A; Aggarwal S; Goswami C; Palanki SD; Arya D; Patil S; Kodagali R
    JCO Glob Oncol; 2021 Jun; 7():849-861. PubMed ID: 34101484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
    Rust K; Spiliopoulou P; Tang CY; Bell C; Stirling D; Phang T; Davidson R; Mackean M; Nussey F; Glasspool RM; Reed NS; Sadozye A; Porteous M; McGoldrick T; Ferguson M; Miedzybrodzka Z; McNeish IA; Gourley C
    BJOG; 2018 Oct; 125(11):1451-1458. PubMed ID: 29460478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
    Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
    Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.